Memo also reportedly mentions vaccines for flu and pneumonia. ...

Key Takeaways CORT's revenues are driven by Korlym, which posted $559.3M in nine-month sales in 2025, up 13.4% y/y.The company expects full-year 2025 revenues of $800M-$850M and sustained Korlym growth.Corcept filed NDAs for relacorilant in Cushing's and ovarian cancer, with FDA decisions due in 2025 and 2026.Corcept Therapeutics (CORT) has been making meaningful progress with its sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism. Cur ...

Key Takeaways Amgen shares jumped almost 16% in a month on strong Q3 results and higher sales guidance.Growing demand for key drugs, new products and biosimilars is driving Amgen's revenue gains.Amgen's expanding pipeline, including MariTide, offers multiple upcoming catalysts.Amgen’s (AMGN) stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also raised its sales guidance for the ...

The FDA approval of LYMPHIR was based on data from Pivotal Study 302 (NCT01871727), which evaluated the efficacy and safety of LYMPHIR in patients with Stage I–III CTCL who had received at least one prior systemic treatment. The study demonstrated an Objective Response Rate (ORR) of 36.2%, with 84% of evaluable patients experiencing a reduction in skin tumor burden. Moreover, LYMPHIR demonstrated meaningful activity on severe pruritus (itchiness), a significant quality of life issue for CTCL patients. Media ...

Treasuries fell as US trading returned to normal after last week’s holiday, with a surge of new corporate bond supply to begin the last month of the year. Most Read from Bloomberg Yields accelerated higher during US morning — led by long-maturity tenors — after Merck & Co. slated an eight-part bond offering that includes 20-, 30- and 40-year tranches. Government bonds globally were already under pressure as Japan’s 10-year yield jumped to the highest level since 2008 on the prospect of a Bank of Japan in ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET) ...

Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound. The single-dose 2.5 and 5 milligram vials will be priced at $299 and $399, respectively, compared to previous prices of $349 and $499. The new pricing will be available on the company's direct-to-consumer platform LillyDirect.LLY is headed for its third-straight daily loss, extending a pullback from last week's record high ...

Key Takeaways Regeneron shares have jumped 21.5% YTD on positive pipeline and regulatory updates.Eylea HD approvals and rising demand help counter pressure from competing ophthalmology therapies.Label expansions for Libtayo and strong Dupixent sales continue to support Regeneron's top-line growth.Shares of Regeneron Pharmaceuticals (REGN) have gained 21.5% year to date compared with the industry’s growth of 10.2%. The stock has also outperformed the sector and the S&P 500 Index during this time frame.The ra ...

Key Takeaways VKTX shares rose 34% in three months on momentum around its investigational obesity drug VK2735.Viking hit fast enrollment milestones for phase III VANQUISH-1 and phase II VENTURE-Oral studies.Viking is also enrolling the VANQUISH-2 study, targeting completion of recruitment in early 2026.Shares of Viking Therapeutics (VKTX) have surged 34% in the past three months, primarily driven by positive investor expectations around its investigational obesity drug, VK2735.Last month, Viking announced t ...